Gray-Market Retatrutide: What the Potency Study, Recalls and FDA Warnings Show

Retatrutide is Eli Lilly's experimental weight-loss injection. It has strong phase 3 results but is not approved anywhere. Lilly plans to apply to the FDA in the first quarter of 2027, yet products sold as "retatrutide" are already widespread online, from telehealth services and from some compounding pharmacies.²³⁵ A preprint published in August 2026 found that people using these non-trial products lost about half as much weight as trial volunteers, and regulators have recorded recalls, contamination concerns and hospitalisations. FDA has also received two unverified reports of deaths.^178101217

This article sets out what that new evidence shows, what FDA and other regulators have done, and why a seller's test certificate cannot tell you whether a vial is safe. It names no seller as a source of supply, gives no dosing information and is not medical advice.

The short version

• The real drug is not yet approved. Lilly told reporters in August 2026 that it "plans to submit its application in the first quarter of 2027." A standard FDA review would follow that. Until approval, retatrutide is legally available only in clinical trials or, for a small number of seriously ill adults, through Lilly's expanded access programme, which needs a doctor's request and agreement from FDA and an ethics board.³⁴¹⁶
• Nothing sold outside a trial is legal in the US. FDA says "retatrutide and cagrilintide cannot be used in compounding under federal law" and that they "have not been found safe and effective for any condition."⁴
• A new potency signal. In US health records, people using retatrutide obtained outside a trial lost an average of 7.2% of body weight at 6–12 months, against 15.5% among trial volunteers. This preprint has not been peer-reviewed.¹
• Problems are documented. A recall of one pharmacy's retatrutide for "lack of assurance of sterility", a cluster of liver injuries in Australia linked to products labelled retatrutide, and at least 14 hospitalisations reported to FDA in connection with the drug. CBS News obtained two FDA reports of deaths in 2026 in people who had used products sold as retatrutide; FDA has not said whether it verified them.^8101217
• A certificate of analysis is not a safety check. It usually describes one sample tested for purity, not the sterility, contaminants or identity of the vial you receive.⁹

Where the real drug stands

Retatrutide activates three hormone receptors (GIP, GLP-1 and glucagon). In the phase 3 TRIUMPH-1 trial, published in the New England Journal of Medicine in September 2026, about 2,300 adults with obesity were followed for 80 weeks. At the highest dose, average weight loss was about a quarter of body weight, against about 4% with placebo.²⁵ Our weight-loss pipeline guide covers the trials and their side effects, including an abnormal skin sensation called dysesthesia.

Lilly has not yet applied; its stated plan is the first quarter of 2027. If the FDA accepts an application then, a standard review would point to a decision around 2028 at the earliest, and approval is not guaranteed.³

What is being sold, and why none of it is legal

"Retatrutide" outside trials reaches people through three main routes:

1. "Research use only" websites. These sell vials labelled "not for human consumption", often alongside bacteriostatic water for mixing injections. Some list the drug under code names; one seller called it "GLP-3R". In an August 2026 warning letter, FDA said: "Despite statements on your product labeling marketing your products for 'research use only' and 'not for human consumption,' evidence obtained from your website establishes that your products are intended to be drugs for human use."⁶ Our explainer on what "research use only" means covers the legal background.
2. Telehealth and wellness clinics. FDA says it has warned "telehealth companies for marketing unapproved drugs such as retatrutide," including direct marketing to consumers.⁴
3. Compounding pharmacies. Compounding normally means a pharmacy prepares a medicine from approved ingredients. Retatrutide is not a component of any approved drug, so FDA says it cannot be compounded. It has also warned ingredient distributors "for selling retatrutide and other GLP-1 drugs to compounders" and outsourcing facilities "for repackaging retatrutide."⁴

Enforcement is growing. JAMA reported in October 2026 that FDA had issued 21 warning letters to retatrutide sellers since December 2024.⁵ Public Citizen found that, as of May 2026, 11 of the 14 sellers it tracked that had received letters were still advertising retatrutide or other unapproved peptides.¹² On 12 August 2026, Lilly announced lawsuits against six companies selling what it called counterfeit, unapproved retatrutide, and said it had referred "more than 200 individuals and entities" to regulators and other authorities. Lilly's chief medical officer said: "What is being sold on the black market is not a medicine — it is entirely unverified, unapproved and not worth the risk."³

The potency study: half the weight loss

In August 2026, researchers at the data company nference posted a preprint analysing de-identified US electronic health records covering 29 million patients. A preprint has not yet been checked by independent reviewers; see how to check whether a study is peer-reviewed.¹

What they found:

• Use is rising fast. Clinical notes for 983 patients mentioned retatrutide. Of 531 with a documented supply route, 378 (71.2%) had obtained it outside a trial, mostly from "online or telehealth vendors (57.4%) and compounding pharmacies (29.4%)." New users grew about 1.8-fold each quarter.¹
• Less weight loss. Matched for age, sex, starting weight, diabetes and other factors, non-trial users lost 7.2% of body weight at 6–12 months. Trial volunteers seen in routine care lost 15.5%. The non-trial figure was similar to matched people starting approved tirzepatide (7.7%).¹
• Heart rate rose in both retatrutide groups, a known effect of the drug, but not in the matched semaglutide or tirzepatide groups. Major heart events were too few to draw conclusions.¹

How much weight to give it. This is an observational study, not a trial. The authors say the data cannot establish what the products contained, the dose people used, whether they kept taking it, or cause and effect. The "trial" group also includes volunteers who were given placebo.¹ The result fits a simple explanation, that many products contain less drug than claimed or the wrong drug, but it does not prove it. Independent testing, described below, points the same way.

What recalls and testing have found

These are small numbers and single cases, so they cannot show how common problems are. Reports to FDA also do not prove that a product caused an illness. Our guide to peptide side effects explains how to read reports like these.

Why "third-party tested" does not mean safe

Sellers often post a certificate of analysis (COA) or a "third-party tested" badge. Even when the certificate is genuine, it has limits:

1. It covers one sample. A COA describes the sample that was tested, often chosen and paid for by the seller, not the vial that arrives at your door.
2. Purity is not identity or strength. In the Australian tests, products that contained real retatrutide still ranged from about half to nearly double the labelled amount.⁹
3. Injections need sterility and endotoxin testing. A purity percentage says nothing about bacteria or the toxins they leave behind. The Australian study did not test for them, and the recall above was for lack of sterility assurance.⁸⁹
4. Unexpected contaminants are not looked for. A standard test checks for the expected molecule. It cannot rule out the kind of unknown contaminant suspected in the Victorian liver cases.¹⁰

Read more in our guides to certificates of analysis and peptide testing.

If you have used non-trial retatrutide

• Get medical help for serious symptoms, such as persistent vomiting, yellowing of the skin or eyes, dark urine, abdominal pain or a racing heart. Tell the clinician exactly what you used and where it came from, and bring the vial if you can.¹⁰
• Report it to FDA MedWatch in the US, or the TGA in Australia.¹⁵
• Talk to a clinician about approved options. Several approved weight-loss medicines exist; our pipeline guide lists them.

Frequently asked questions

Is retatrutide FDA-approved?

No. Lilly plans to apply in the first quarter of 2027. Until it is approved, retatrutide is legally available in the US only through clinical trials or Lilly's limited expanded access programme, which needs a doctor's request and agreement from FDA and an ethics board.³⁴¹⁶

Can a pharmacy legally compound retatrutide?

No. FDA says retatrutide "cannot be used in compounding under federal law" because it is not a component of an approved drug.⁴

Is "research" retatrutide the same as Lilly's drug?

You cannot know. Tested products have contained far more or less than the label, or a different drug entirely, and none has been tested for safety in the way trial supplies are.⁵⁹

Why did people in the study lose less weight?

The study cannot say. Possible reasons include products containing less drug than claimed, different doses, or people stopping treatment. The authors note they could not check product contents or adherence.¹

Does a certificate of analysis prove a product is safe?

No. It usually reports purity for one sample. It does not show sterility, endotoxin levels or unknown contaminants in the vial you receive.⁸⁹